MC
MYOV

Matisse Capital’s Myovant Sciences Ltd. MYOV Stock Holding History

Matisse Capital’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-32,750
Closed -$508K – 199
2019
Q4 		$508K Buy
+32,750
New +$330K 0.36% 59
2018
Q4 		– Sell
-15,250
Closed -$405K – 120
2018
Q3 		$405K Hold
15,250
– – 0.36% 70
2018
Q2 		$349K Buy
+15,250
New +$333K 0.28% 79

Other funds holding MYOV

Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Matisse Capital's MYOV Position: Q1 2020 in Review

Matisse Capital sold out of Myovant Sciences Ltd. (MYOV) in Q1 2020, closing a stake of 32,750 shares — an estimated $508K sold.

Matisse Capital first reported a position in MYOV in Q2 2018 and held it in 3 quarters. The position peaked at $508K in Q4 2019. 75 funds tracked by Wall St. Rank hold MYOV as of Q1 2020.

  • Matisse Capital reported no remaining Myovant Sciences Ltd. position as of Q1 2020 after selling out during the quarter.
  • Matisse Capital sold 32,750 Myovant Sciences Ltd. shares in Q1 2020, an estimated $508K.
  • Matisse Capital first reported a position in Myovant Sciences Ltd. in Q2 2018 and held it in 3 quarters.
  • Matisse Capital's Myovant Sciences Ltd. position peaked at $508K in Q4 2019.
  • 75 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2020.

Based on Matisse Capital's 13F filing for Q1 2020, filed 7 May 2020.